Effect of Obesity on In-Hospital Mortality in Patients with Cardiogenic Shock Complicating AMI Obesity is paradoxically associated with favorable mortality.

Slides:



Advertisements
Similar presentations
Does Preoperative Hemoglobin Value Predict Postoperative Cardiovascular Complications after Total Joint Arthroplasty? Kishor Gandhi MD, MPH, Eugene Viscusi.
Advertisements

The Influence of Radial vs. Femoral Access on Acute Blood Loss in Patients Undergoing Percutaneous Coronary Intervention Amit Nanda 1, Eric Novak MS 2,
The Influence of Radial vs. Femoral Access on Acute Blood Loss in Patients Undergoing Percutaneous Coronary Intervention Amit Nanda 1, Amit P. Amin 2,
FAME 2 year Objective:To investigate the 2-year outcome of PCI guided by FFR in patients with multivessel CAD. Study:Multicenter, single blind, randomized.
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
Association Between Diabetes, Obesity, and Short-Term Outcomes Among Patients Surgically Treated for Ankle Fracture by Matthew J. Cavo, Justin P. Fox,
Type 2 diabetes and high blood pressure How explosive is the cocktail?
Cost-Effectiveness of Treatment Strategies for Comorbid Diabetes and Dyslipidemia Part 1.
Could an antianginal metabolic agent have an impact on prognosis in ischemic patients? Beneficial effects of trimetazidine in patients with acute myocardial.
Impact of Prior Myocardial Infarction Among Patients with Acute Myocardial Infarction Treated in Contemporary Practice: A Report from the ACTION Registry.
Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.
Distribution of metabolic syndrome (MS) components by age and gender Zhao D, et al. Am J Cardiol 2007;100:835– 839.
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.
Short- and Long-Term Mortality After Myocardial Infarction in Patients With and Without Diabetes Featured Article: Sjoerd T. Nauta, M.S.C., Jaap W. Deckers,
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: The effects of New York’s bypass surgery provider.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early and long-term clinical outcomes associated.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Has Public Reporting of Hospital Readmission Rates.
Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.
Insights from a Contemporary STEMI Prospective Registry
Landon Marshall, Pharm. D. , Matt Hill, Pharm. D. , Jim Wilson, Pharm
IABP-SHOCK II Score Stratifies Patient Risk in CS after AMI
The MASS-DAC Study.
Emory University School of Medicine
Copyright © 2005 American Medical Association. All rights reserved.
Clinical need for determination of vulnerable plaques
Successful CTO PCI Associated with Lower Mortality Risk
Impella 2.5® Device Is Associated with Improved Survival in AMICS
What about CMR in patients with acute MI?
EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.
Valsartan in Acute Myocardial Infarction Trial Investigators
Andrew McNeice1,2, Imad J. Nadra1,2, Simon D
Figure 4 BMI and mortality in patients with heart failure
A: Epidemiology update
Clopidogrel Reduces ADP-Induced Expression of Platelet-derived CD40L
Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.
VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =
Nat. Rev. Cardiol. doi: /nrcardio
Fewer PCIs After Public Reporting Changes in NY
SMILE Trial design: NSTEMI patients were randomized to complete revascularization during the index procedure (i.e., 1-stage revascularization; n = 264)
Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);
Figure 4 Observational studies on multiple treatment strategies
Role of Stenting in Acute MI: PAMI Stent Pilot Trial
Mancini JG, et al. Am J Cardiol.
Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.
No Financial Disclosure or Conflict of Interest
Characteristics of elderly patients prescribed statins after acute myocardial infarction (AMI) in Quebec, Ontario and British Columbia - Part I Zheng.
Nat. Rev. Cardiol. doi: /nrcardio
Maintenance of Long-Term Clinical Benefit with
Nat. Rev. Cardiol. doi: /nrcardio
Characteristics of 21,484 Patients With MI Who Survived for >30 Days After Discharge, by Calendar Year - Part I Soko Setoguchi, et al. J Am Coll Cardiol.
Nat. Rev. Cardiol. doi: /nrcardio
SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.
DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.
Baseline Characteristics of the Patients – Part I
IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
EMPA-REG OUTCOME: Cumulative incidence of the primary outcome
Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Additional benefit of PCSK9 inhibition in high risk patients after myocardial infarction A FOURIER subanalysis Primary endpoint: composite of CV death,
MRRs and EMRRs for women with ACS
A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.
Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.
Prevalence of acute myocardial infarction (AMI) or other cardiovascular events (CVEs) according to the presence of acute respiratory failure (ARF) and.
FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.
Prevalence of acute myocardial infarction (AMI) or other cardiovascular events (CVEs) according to a) Pneumonia Severity Index (PSI) risk classes and b)
Cardiovascular Epidemiology and Epidemiological Modelling
Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.
Presentation transcript:

Effect of Obesity on In-Hospital Mortality in Patients with Cardiogenic Shock Complicating AMI Obesity is paradoxically associated with favorable mortality outcomes in acute myocardial infarction (AMI). Association between obesity & in-hospital mortality among patients with cardiogenic shock (CS) complicating AMI (N=290,894) was retrospectively studied. National Inpatient Sample database from the 2004 - 13 Obese patients (n=25,835, 8.9%) had more cardiovascular (CV) comorbidities & more likely to receive revascularization than non-obese patients (73.0% vs 63.4%). Obese patients had higher prevalence of CV risks including dyslipidemia, previous MI, hypertension, and previous PCI. Obese patients had lower risk-adjusted in-hospital mortality rate (28.2% vs 36.5%, p<0.001). Obese patients in this analysis were younger, more likely to receive revascularization, which may explain the observed “obesity paradox.” Chatterjee K et al. Am J Cardiol. 2017. NPS-043-17